Login / Signup

Advances in therapeutic targeting of immune checkpoints receptors within the CD96-TIGIT axis: clinical implications and future perspectives.

Pooya FarhangniaMahzad AkbarpourMahboubeh YazdanifarAmir Reza ArefAli-Akbar DelbandiNima Rezaei
Published in: Expert review of clinical immunology (2022)
CD96-TIGIT axis regulates anti-tumor immune responses. Thus, the receptors within this axis are the potential candidates for cancer immunotherapy. Combining the inhibition of CD96-TIGIT with anti-PD-1/PD-L1 mAbs and chemotherapy drugs has shown relatively effective results in the context of preclinical studies and tumor models.
Keyphrases
  • immune response
  • nk cells
  • stem cells
  • dendritic cells
  • radiation therapy
  • mesenchymal stem cells
  • climate change
  • bone marrow
  • drug delivery
  • case control